Creative BioMart to Present at
                        BIO-Europe Spring Creative BioMart to Present at AACR Annual Meeting|Apr. 5-10, 2024|Booth #2953

Recombinant Human TNFSF14 293 Cell Lysate

Cat.No. : TNFSF14-891HCL
  • Specification
  • Gene Information
  • Related Products
Description : Antigen standard for tumor necrosis factor (ligand) superfamily, member 14 (TNFSF14), transcript variant 1 is a lysate prepared from HEK293T cells transiently transfected with a TrueORF gene-carrying pCMV plasmid and then lysed in RIPA Buffer. Protein concentration was determined using a colorimetric assay. The antigen control carries a C-terminal Myc/DDK tag for detection.
Source : HEK 293 cells
Species : Human
Components : This product includes 3 vials: 1 vial of gene-specific cell lysate, 1 vial of control vector cell lysate, and 1 vial of loading buffer. Each lysate vial contains 0.1 mg lysate in 0.1 ml (1 mg/ml) of RIPA Buffer (50 mM Tris-HCl pH7.5, 250 mM NaCl, 5 mM EDTA, 50 mM NaF, 1% NP40). The loading buffer vial contains 0.5 ml 2X SDS Loading Buffer (125 mM Tris-Cl, pH6.8, 10% glycerol, 4% SDS, 0.002% Bromophenol blue, 5% beta-mercaptoethanol).
Size : 0.1 mg
Storage Instruction : Store at -80°C. Minimize freeze-thaw cycles. After addition of 2X SDS Loading Buffer, the lysates can be stored at -20°C. Product is guaranteed 6 months from the date of shipment.
Applications : ELISA, WB, IP. WB: Mix equal volume of lysates with 2X SDS Loading Buffer. Boil the mixture for 10 min before loading (for membrane protein lysates, incubate the mixture at room temperature for 30 min). Load 5 ug lysate per lane.
Gene Name : TNFSF14 tumor necrosis factor (ligand) superfamily, member 14 [ Homo sapiens ]
Official Symbol : TNFSF14
Synonyms : TNFSF14; tumor necrosis factor (ligand) superfamily, member 14; tumor necrosis factor ligand superfamily member 14; CD258; HVEM L; LIGHT; LTg; delta transmembrane LIGHT; herpesvirus entry mediator A; herpesvirus entry mediator ligand; herpesvirus entry mediator-ligand; herpes virus entry mediator ligand; ligand for herpesvirus entry mediator; tumor necrosis factor receptor-like 2; tumor necrosis factor superfamily member LIGHT; TR2; HVEML;
Gene ID : 8740
mRNA Refseq : NM_003807
Protein Refseq : NP_003798
MIM : 604520
UniProt ID : O43557
Chromosome Location : 19p13.3
Pathway : Cytokine-cytokine receptor interaction, organism-specific biosystem; Cytokine-cytokine receptor interaction, conserved biosystem; Herpes simplex infection, organism-specific biosystem; Herpes simplex infection, conserved biosystem;

For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.

Inquiry

  • Q&As
  • Reviews

Q&As (7)

Ask a question
What are the primary changes induced by TNFSF14 in the tumor microenvironment? 05/19/2022

TNFSF14, when delivered to or expressed within tumors, causes significant changes primarily through vascular normalization and generation of tertiary lymphoid structures.

What challenges remain in utilizing TNFSF14 for cancer immunotherapy? 07/02/2021

While investigators have used multiple vectors to deliver TNFSF14 to tumor tissues, there are still improvements needed, and components within the human tumor microenvironment may impede translational efforts.

What does TNFSF14 stand for? 02/05/2021

TNFSF14 stands for Tumor Necrosis Factor Superfamily Member 14.

How can TNFSF14 synergize with other immunotherapy modalities? 02/22/2020

TNFSF14's changes in the tumor microenvironment can synergize with methods inducing anti-tumor immune responses, such as checkpoint inhibitors and tumor vaccines, improving immunotherapeutic strategies against cancer.

In what context has TNFSF14 been utilized to combat cancer? 02/06/2018

TNFSF14 has been used in multiple tumor models, where it can be combined with other immunotherapy modalities to clear established solid tumors and treat metastatic events.

How long has TNFSF14 been in pre-clinical development? 06/11/2017

TNFSF14 has been in pre-clinical development for over a decade.

What is the primary promise of TNFSF14 in the field of cancer immunotherapy? 08/15/2016

TNFSF14 shows promise in enhancing treatment approaches in cancer immunotherapy.

Customer Reviews (3)

Write a review
Reviews
07/28/2020

    The extended longevity of results gave us the confidence to delve deeper into complex biological processes.

    08/01/2018

      It was reassuring to know that the product's effects persisted, allowing for thorough and comprehensive research.

      06/19/2016

        The ability to obtain enduring results positively influenced the depth of our investigations.

        Ask a Question for All TNFSF14 Products

        Required fields are marked with *

        My Review for All TNFSF14 Products

        Required fields are marked with *

        0

        Inquiry Basket

        cartIcon
        logo

        FOLLOW US

        Terms and Conditions        Privacy Policy

        Copyright © 2024 Creative BioMart. All Rights Reserved.

        Contact Us

        • /

        Stay Updated on the Latest Bioscience Trends